Trade

with

Inovio Pharmaceuticals Inc
(NASDAQ: INO)
AdChoices
11.31
+0.11
+0.98%
After Hours :
11.31
0.00
0.00%

Open

11.49

Previous Close

11.20

Volume (Avg)

521.10k (1.57M)

Day's Range

11.06-11.55

52Wk Range

8.51-63.20

Market Cap.

676.47M

Dividend Rate ( Yield )

-

Beta

3.13

Shares Outstanding

60.40M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Biotechnology
Highlights
Analyst Recommendation: Buy
    • Revenue

    • 13.47M

    • Net Income

    • -66.03M

    • Market Cap.

    • 676.47M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -390.34

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 3.13

    • Forward P/E

    • -11.43

    • Price/Sales

    • 34.84

    • Price/Book Value

    • 5.55

    • Price/Cash flow

    • -35.59

      • EBITDA

      • -17.45M

      • Return on Capital %

      • -70.27

      • Return on Equity %

      • -89.87

      • Return on Assets %

      • -70.27

      • Book Value/Share

      • 2.02

      • Shares Outstanding

      • 60.40M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/21/2014
      Buy
        • 1 Year Price Target

        • 19.00

        • Credit Rating

        • -

        • Analysts

        • 3

        • EPS Estimate

        • -0.98

        • Cashflow Estimate

        • -0.16

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 383.90

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • 45.05

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 100.00

            • 82.75

            • Pre-Tax Margin

            • -390.59

            • 39.38

            • Net Profit Margin

            • -390.34

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • 100.00

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -335.60

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.76

              • Current Ratio

              • 9.73

              • 2.92

              • Quick Ratio

              • 9.63

              • 2.35

              • Interest Coverage

              • -

              • 38.02

              • Leverage Ratio

              • 1.17

              • 2.21

              • Book Value/Share

              • 2.02

              • 4.79

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -9.69

                • 243.90

                • P/E Ratio 5-Year High

                • -12.55

                • 634.30

                • P/E Ratio 5-Year Low

                • -1.11

                • 124.82

                • Price/Sales Ratio

                • 37.88

                • 9.29

                • Price/Book Value

                • 6.04

                • 8.39

                • Price/Cash Flow Ratio

                • -35.59

                • 49.75

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • -89.87

                    (-65.40)

                  • 37.63

                    (27.20)

                  • Return on Assets %

                    (5-Year Average)

                  • -70.27

                    (-45.70)

                  • 17.22

                    (13.81)

                  • Return on Capital %

                    (5-Year Average)

                  • -89.87

                    (-61.90)

                  • 21.78

                    (17.31)

                  • Income/Employee

                  • -

                  • 117.08k

                  • Inventory Turnover

                  • -

                  • 1.48

                  • Asset Turnover

                  • 0.18

                  • 0.55

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  -19.54M
                  Operating Margin
                  -145.12
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  -35.59
                  Ownership

                  Institutional Ownership

                  18.54%

                  Top 10 Institutions

                  13.90%

                  Mutual Fund Ownership

                  12.26%

                  Float

                  94.25%

                  5% / Insider Ownership

                  7.38%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • SPDR® S&P Biotech ETF

                  •  

                    1,496,279

                  • -9.83

                  • 2.75

                  • iShares Russell 2000 (AU)

                  •  

                    909,629

                  • -1.81

                  • 1.67

                  • Vanguard Total Stock Mkt Idx

                  •  

                    876,919

                  • 0.00

                  • 1.45

                  • Vanguard Extended Market Index Fund

                  •  

                    522,220

                  • 1.98

                  • 0.86

                  • iShares Russell 2000 Growth

                  •  

                    373,705

                  • -1.57

                  • 0.69

                  • TIAA-CREF Enhanced Lg Cp Gr Idx

                  •  

                    269,248

                  • 19.67

                  • 0.45

                  • CREF Stock

                  •  

                    259,735

                  • 1.18

                  • 0.43

                  • Fidelity Spartan® Extended Mkt Indx Fd

                  •  

                    193,345

                  • 0.00

                  • 0.32

                  • Vanguard Instl Total Stock Market Index

                  •  

                    174,707

                  • -1.77

                  • 0.29

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • State Street Corp

                  •  

                    2,295,070

                  • +79.00%

                  • 3.80

                  • Vanguard Group, Inc.

                  •  

                    1,678,440

                  • +18.25%

                  • 2.78

                  • Morgan Stanley Smith Barney LLC

                  •  

                    740,946

                  • +61.62%

                  • 1.23

                  • TIAA-CREF Investment Management LLC

                  •  

                    701,634

                  • +1.48%

                  • 1.16

                  • Goldman, Sachs & Co.

                  •  

                    475,648

                  • +841.26%

                  • 0.79

                  • Teachers Advisors, Inc.

                  •  

                    309,725

                  • -73.39%

                  • 0.51

                  • Geode Capital Management, LLC

                  •  

                    300,888

                  • +34.82%

                  • 0.50

                  • Security Investors, LLC

                  •  

                    224,564

                  • +4,179.86%

                  • 0.37

                  • BlackRock Advisors LLC

                  •  

                    178,129

                  • +508,840.00%

                  • 0.30

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Biotechnology

                  Type

                  Speculative Growth

                  Style

                  Small Growth

                  Inovio Biomedical Corporation was originally incorporated on June 29, 1983, under the laws of California as Biotechnologies & Experimental Research, Inc. The entity changed its corporate name to BTX, Inc. on December 10, 1991, and Ge...morenetronics, Inc. on February 8, 1994. On April 14, 1994, the board of directors approved a share exchange agreement with Consolidated United Safety Technologies Inc. On September 2, 1997, it listed on the Toronto Stock Exchange as Genetronics Biomedical Ltd, under the laws of British Columbia, Canada, which wholly owned Genetronics, Inc. On June 15, 2001, it completed a change in jurisdiction of incorporation from British Columbia, Canada, to the state of Delaware and became Genetronics Biomedical Corporation, a Delaware corporation. On January 17, 2003, Genetronics volun...moretarily de-listed from the Toronto Stock Exchange. On March 31, 2005, its corporate name changed from Genetronics Biomedical Corporation to Inovio Biomedical Corporation. On June 1, 2009, it completed the acquisition of VGX Pharmaceuticals, Inc. (‘VGX’), a privately-held company, pursuant to the terms of an Amended and Restated Agreement and Plan of Merger dated December 5, 2008, as further amended on March 31, 2009 by and among Inovio, Inovio’s wholly-owned subsidiary Inovio Acquisition, LLC and VGX (the ‘Merger’). Upon the closing of the Merger, Inovio Acquisition, LLC assumed all of VGX’s business, properties and assets and assumed its obligations, changed its name to VGX Pharmaceuticals, LLC, and remains a wholly-owned subsidiary of the Company, utilizing a single, integrated management team with Inovio. On May 14, 2010, the entity changed its corporate name to Inovio Pharmaceuticals, Inc. The Company is engaged in the development of a new generation of vaccines and immune therapies, called synthetic vaccines, focused on cancers and infectious diseases. Its DNA-based SynCon technology is designed to provide universal protection against known as well as new unmatched strains of pathogens such as influenza. These synthetic vaccines, in combination with its proprietary electroporation delivery, have been shown in humans to generate best-in-class immune responses with a favorable safety profile. Its preclinical development and clinical programs include cervical dysplasia/cancer (therapeutic), influenza (preventive), prostate cancer (therapeutic), leukemia (therapeutic), hepatitis C virus, hepatitis B virus, HIV, and malaria vaccines. The Company faces competition from several development-stage and established enterprises, including major pharmaceutical and biotechnology firms, which are actively engaged in infectious disease and cancer vaccine research and development. Any pharmaceutical products that the Company develops will require regulatory clearances prior to clinical trials and additional regulatory approvals prior to commercialization. The Company's clinical programs include cervical dysplasia (therapeutic), avian influenza (preventive), prostate cancer (therapeutic), leukemia (therapeutic), hepatitis C virus (HCV) and HIV vaccines.lessless

                  Key People

                  Dr. J. Joseph Kim,PhD

                  CEO/Director/President

                  Dr. Avtar Dhillon,M.D.

                  Chairman of the Board/Director

                  Peter D. Kies

                  CFO/Chief Accounting Officer

                  Simon X. Benito

                  Director

                  Adel A.F. Mahmoud,M.D.,PhD

                  Director

                  • Inovio Pharmaceuticals Inc

                  • 1787 Sentry Parkway West Building18

                  • Blue Bell, PA 19422-2200

                  • USA.Map

                  • Phone: +1 267 440-4200

                  • Fax: +1 267 440-4242

                  • inovio.com

                  Incorporated

                  1983

                  Employees

                  71

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: